Characterization and preclinical development of LY2603618: A selective and potent Chk1 inhibitor

Investigational New Drugs

Volumn 32, Issue 2, 2014, Pages 213-226

  King, Constance ^a   Diaz, Henry ^a   Barnard, Darlene ^a   Barda, David ^a   Clawson, David ^a   Blosser, Wayne ^a   Cox, Karen ^a   Guo, Sherry ^a   Marshall, Mark ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Chk1 inhibitor; DNA damage induced cytotoxicity; G2 M cell cycle checkpoint; LY2603618

Indexed keywords

CHECKPOINT KINASE 1; DNA; DOXORUBICIN; GEMCITABINE; PROTEIN P53; RABUSERTIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CELL SPECIFICITY; CELL STRAIN HT29; CHROMOSOME CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; METAPHASE; MITOSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; RNA INTERFERENCE; SINGLE DRUG DOSE; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA DAMAGE; DOXORUBICIN; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896383123     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0036-7     Document Type: Article

References (33)

1. Dai Y, Grant S (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res Off J Am Assoc Cancer Res 16(2):376-383. doi: 10.1158/1078-0432.CCR-09-1029
2. Carrassa L, Damia G (2011) Unleashing Chk1 in cancer therapy. Cell Cycle 10(13):2121-2128
3. Nam EA, Cortez D (2011) ATR signalling: more than meeting at the fork. Biochem J 436(3):527-536. doi: 10.1042/BJ20102162
4. Garrett MD, Collins I (2011) Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 32(5):308-316. doi: 10.1016/j.tips.2011.02.014
5. Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A (2006) Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 5(21):2543-2547
6. Niida H, Tsuge S, Katsuno Y, Konishi A, Takeda N, Nakanishi M (2005) Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem 280(47):39246-39252. doi: 10.1074/jbc.M505009200
7. Ge XQ, Blow JJ (2010) Chk1 inhibits replication factory activation but allows dormant origin firing in existing factories. J Cell Biol 191(7):1285-1297. doi: 10.1083/jcb.201007074
8. Maya-Mendoza A, Petermann E, Gillespie DA, Caldecott KW, Jackson DA (2007) Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J 26(11):2719-2731. doi: 10.1038/sj.emboj.7601714
9. Petermann E, Woodcock M, Helleday T (2010) Chk1 promotes replication fork progression by controlling replication initiation. Proc Nat Acad Sci U S A 107(37):16090-16095. doi: 10.1073/pnas.1005031107
10. Forment JV, Blasius M, Guerini I, Jackson SP (2011) Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation. PloS one 6(8):e23517. doi: 10.1371/journal.pone.0023517
11. Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36(17):5678-5694. doi: 10.1093/nar/gkn550
12. Wei Y, Yu L, Bowen J, Gorovsky MA, Allis CD (1999) Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 97(1):99-109
13. Tang J, Erikson RL, Liu X (2006) Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1). Proc Nat Acad Sci U S A 103(32):11964-11969. doi: 10.1073/pnas. 0604987103
14. Keegan KS (2002) Heteroaryl urea Chk1 inhibitors for use as radiosensitizers and chemosensitizers. PCT/US2002/006452
15. Diaz F (2006) Heteroaryl urea derivatives useful for inhibiting Chk1. US Patent PCT/US2006/011584
16. Low J, Shuguang H, Dowless M, Blosser W, Vincent T, Davis S, Hodson J, Koller E, Marcusson E, Blanchard K, Stancato L (2007) High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides. J Biomol Screen 12(6):775-788. doi: 10.1177/1087057107302675
17. Gallagher SR (2012) One-dimensional SDS gel electrophoresis of proteins. Current protocols in protein science/editorial board, John E Coligan [et al.] Chapter 10:Unit 10 11 11-44. doi: 10.1002/0471140864.ps1001s68
18. Li G, Hasvold LA, Tao ZF, Wang GT, Gwaltney SL 2nd, Patel J, Kovar P, Credo RB, Chen Z, Zhang H, Park C, Sham HL, Sowin T, Rosenberg SH, Lin NH (2006) Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Bioorg Med Chem Lett 16(8):2293-2298. doi: 10.1016/j.bmcl.2006.01.028
19. Boyle RGI, Hassan J, Cherry M (2003) Diarylurea compounds and derivatives as Chk-1 inhibitors for the treatment of cancer. Israel Patent
20. Diaz F, Farouz FS, Holcomb R, Kesicki EA, Ooi HC, Rudolph A, Stappenbeck F, Thorsett E, Gaudino JJ, Fischer KL, Cook AW (2006) Heteroaryl urea derivatives useful for inhibiting Chkl. Israel Patent, 5 October 2006
21. Keegan KS, Kesicki EA, Gaudino JJ, Cook AW, Cowen SD, Burgess LE (2002) Aryl and heteroaryl urea Chk1 inhibitors for use as radiosensitizers and chemosensitizers. Israel Patent, 12.09.2002
22. Peddibhotla S, Lam MH, Gonzalez-Rimbau M, Rosen JM (2009) The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis. Proc Nat Acad Sci U S A 106(13):5159-5164. doi: 10.1073/pnas.0806671106
23. Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le Huerou Y, Mohr PJ, Wang B, Blake JF, Lyon MA, Gunawardana I, Chicarelli M, Wallace E, Gross S (2011) Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res 19(7):349-363
24. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR (1993) Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Nat Acad Sci U S A 90(9):3988-3992
25. Groth A, Lukas J, Nigg EA, Sillje HH, Wernstedt C, Bartek J, Hansen K (2003) Human Tousled like kinases are targeted by an ATM- and Chk1-dependent DNA damage checkpoint. EMBO J 22(7):1676-1687. doi: 10.1093/emboj/cdg151
26. Tao ZF, Lin NH (2006) Chk1 inhibitors for novel cancer treatment. Anti-Cancer Agents Med Chem 6(4):377-388
27. Chen T, Stephens PA, Middleton FK, Curtin NJ (2012) Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today 17(5-6):194-202. doi: 10.1016/j.drudis.2011.12.009
28. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, Maybaum J (2009) Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 8(1):45-54. doi: 10.1158/1535-7163.MCT-08-0662
29. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS (2005) Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65(15):6835-6842. doi: 10.1158/0008-5472.CAN-04-2246
30. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, Robertson S, Murray L, Karnitz LM (2007) Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6(1):104-110
31. Ross WE, Bradley MO (1981) DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta 654(1):129-134
32. Brooks K, Oakes V, Edwards B, Ranall M, Leo P, Pavey S, Pinder A, Beamish H, Mukhopadhyay P, Lambie D, Gabrielli B (2012) A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene. doi: 10.1038/onc.2012.72
33. Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, Hurt K, Hynes SM, Anthony SP, McKane S (2012) Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Investig New Drugs. doi: 10.1007/s10637-012-9815-9